Abstract
The bisphosphonates represent a new class of pharmacologic agents that inhibit bone resorption and decrease the rate of bone turnover, making them of potential clinical value in the treatment of osteoporosis. Among these drugs, the new aminobisphosphonate alendronate (Fosamax(TM)) preferentially inhibits bone resorption at doses that do not inhibit mineralization, thus permitting continuous administration. In extensive clinical use, alendronate has been shown to reduce the turnover, and increase the density, of bone, and reduces the incidence of new vertebral fractures and loss of height in osteoporotic postmenopausal women.
| Original language | English |
|---|---|
| Pages (from-to) | 103-118 |
| Number of pages | 16 |
| Journal | Today's Therapeutic Trends |
| Volume | 14 |
| Issue number | 2 |
| State | Published - 1996 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Current investigative and clinical experience with alendronate in osteoporosis. / Recker, Robert R.
In: Today's Therapeutic Trends, Vol. 14, No. 2, 1996, p. 103-118.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Current investigative and clinical experience with alendronate in osteoporosis
AU - Recker, Robert R.
PY - 1996
Y1 - 1996
N2 - The bisphosphonates represent a new class of pharmacologic agents that inhibit bone resorption and decrease the rate of bone turnover, making them of potential clinical value in the treatment of osteoporosis. Among these drugs, the new aminobisphosphonate alendronate (Fosamax(TM)) preferentially inhibits bone resorption at doses that do not inhibit mineralization, thus permitting continuous administration. In extensive clinical use, alendronate has been shown to reduce the turnover, and increase the density, of bone, and reduces the incidence of new vertebral fractures and loss of height in osteoporotic postmenopausal women.
AB - The bisphosphonates represent a new class of pharmacologic agents that inhibit bone resorption and decrease the rate of bone turnover, making them of potential clinical value in the treatment of osteoporosis. Among these drugs, the new aminobisphosphonate alendronate (Fosamax(TM)) preferentially inhibits bone resorption at doses that do not inhibit mineralization, thus permitting continuous administration. In extensive clinical use, alendronate has been shown to reduce the turnover, and increase the density, of bone, and reduces the incidence of new vertebral fractures and loss of height in osteoporotic postmenopausal women.
UR - http://www.scopus.com/inward/record.url?scp=0029827533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029827533&partnerID=8YFLogxK
M3 - Review article
VL - 14
SP - 103
EP - 118
JO - Today's Therapeutic Trends
JF - Today's Therapeutic Trends
SN - 0741-2320
IS - 2
ER -